The Effectiveness of Laboratory Parameters in Predicting the in-Hospital Mortality of Iranian Patients with Coronavirus Disease 2019 (COVID-19)
Keywords:
2019‐nCoV, Laboratory Characteristics, MortalityAbstract
Background. The novel coronavirus 2019-nCoV (now SARS-CoV-2) has spread globally and affected healthcare systems worldwide. Due to lack of long-term immunization and effective specific treatments for the COVID-19 disease, there is a need of identifying the patients who are at the risk of a fatal outcome, according to the available epidemiological data and laboratory parameters.
Objective. Thus, we aimed to evaluate the prognostic value of epidemiological data and laboratory parameters for in-hospital case fatality in patients with COVID-19.
Materials and Methods. A retrospective cohort of patients with COVID-19 admitted to the Shahid Mostafa Khomeini Hospital of Ilam University of Medical Sciences from February 29 until March 29, 2020 was performed. Epidemiologic data and laboratory results were collected. Univariate and multivariate logistic regression models were performed to evaluate the prognostic value of the laboratory parameters for inhospital death.
Results. A total of 256 Iranian COVID-19 patients were included in the evaluation; 38 of them died, resulting in a in-hospital case-fatality rate of 14.8%. The univariate analysis showed that advanced age [OR=1.04, 95% CI: 1.02, 1.06, P=0.001], smoking [OR=4.041, 95% CI: 1.546-10.563, P=0.004], white blood cells [OR=0.941, 95% CI: 0.904-0.980, P =0.003] and hematocrit [OR=1.060, 95% CI: 1.009-1.113, P=0.020] were positively associated with the risk of a fatal outcome. Multivariate logistic regression analysis revealed that COVID-19 patients with an elevated white blood cell count and elevated hemoglobin level had 1% and 9% greater risk of an in-hospital death for each elevated unit [OR=1.07; 95 %CI: 1.024-1.088, P =0.002 and OR=1.379; 95% CI 0.064-1.788, P =0.015, respectively].
Conclusions. An increase in white blood cell count and an increase in hemoglobin level might be independent risk factors for in-hospital death in Iranian patients with COVID-19. Further studies are necessary in order to conferm the prognostic value of the variables discussed.
References
1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382(13): 1199-207. doi: 10.1056/ NEJMoa2001316. Epub 2020 Jan 29.
2. Eurosurveill Editorial Team. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill 2020; 25(5): 200131e. doi: 10.2807/15607917.ES.2020.25.5.200131e. Epub 2020 Jan 31.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020; 92: 214-7. doi: 10.1016/j.ijid.2020.01.050. Epub 2020 Jan 30.
5. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematology 2020. doi: 10.1002/ ajh.25847. Epub ahead of print.
6. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020 Jun 25; 58(7): 1131-4. doi: 10.1515/cclm-2020-0198.
7. World Health Organization (WHO). Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: Interim guidance. World Health Organization, January 28, 2020.
8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9. Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020; 55(5): 2000524. doi: 10.1183/13993003.00524-2020. Epub 2020 May 7.
10. Polosa R, Caci G. COVID-19: counter-intuitive data on smoking prevalence and therapeutic implications for nicotine. Intern Emerg Med 2020: 1-4. doi: 10.1007/s11739-020-02361-9. Epub 2020 May 19.
11. Chen L, Yu J, He W, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia 2020; 34(8): 2173-83. doi: 10.1038/s41375-020 -0911-0. Epub 2020 Jun 16.
12. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020; 18: 20. doi: 10.18332/ tid/119324. Epub 2020 Mar 20.
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(1029): 1954-62. https:// doi.org/10.1016/S0140-6736(20)30566-3.
14. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID19. J Infect 2020; 81(1):e6-e12. doi: 10.1016/j. jinf.2020.04.002. Epub 2020 Apr 10.
15. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 19(5): 529-39. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2.
16. Zhao Y, Nie H-X, Hu K, et al. Abnormal immunity of non-survivors with COVID-19: predictors for mortality. Infect Dis Poverty 2020; 9: 108.
https://doi.org/10.1186/s40249-020-00723-1.
17. Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020 Dec; 26(12): 1622-9. https://doi.org/10.1016/j. cmi.2020.07.016. Epub 2020 Jul 22.
18. Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol 2020; 55(6): 327-31. 10.1097/rli.0000000000000672.
19. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-768. doi: 10.1093/cid/ciaa248.
20. Zhang Jj, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy 2020; 75(7):17301741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
21. Yang A-P, Liu J, Tao W, Li H-m. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020: 106504. doi: 10.1016/j.intimp.2020.106504. Epub 2020 Apr 13.
22. Zhang X, Zhang F, Qiao W, Zhang X, Zhao Z, Li M. Low Hematocrit Is a Strong Predictor of Poor Prognosis in Lung Cancer Patients. Biomed Res Internat 2018; 2018: 6804938. doi: 10.1155/2018/6804938.
23. Chen B, Dai D, Tang H, Ai X, Chen X, Zhang X, et al. Pretreatment hematocrit is superior to hemoglobin as a prognostic factor for triple negative breast cancer. PloS One 2016; 11(11): e0165133. doi: 10.1371/journal.pone.0165133.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.